Corbus Pharmaceuticals (NASDAQ:CRBP) Now Covered by Analysts at StockNews.com

StockNews.com began coverage on shares of Corbus Pharmaceuticals (NASDAQ:CRBPGet Rating) in a research report issued to clients and investors on Thursday. The brokerage set a “hold” rating on the biopharmaceutical company’s stock.

Separately, Zacks Investment Research upgraded Corbus Pharmaceuticals from a “hold” rating to a “buy” rating and set a $0.50 price target on the stock in a research report on Friday, March 11th. Three research analysts have rated the stock with a hold rating and two have assigned a buy rating to the stock. According to MarketBeat, Corbus Pharmaceuticals has an average rating of “Hold” and an average price target of $1.83.

Shares of CRBP stock opened at $0.40 on Thursday. The firm has a market cap of $50.10 million, a P/E ratio of -1.03 and a beta of 1.91. Corbus Pharmaceuticals has a fifty-two week low of $0.30 and a fifty-two week high of $2.29. The business’s 50 day moving average price is $0.41 and its 200-day moving average price is $0.67. The company has a debt-to-equity ratio of 0.23, a quick ratio of 5.89 and a current ratio of 5.89.

Corbus Pharmaceuticals (NASDAQ:CRBPGet Rating) last released its quarterly earnings results on Tuesday, March 8th. The biopharmaceutical company reported ($0.08) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.11) by $0.03. Corbus Pharmaceuticals had a negative return on equity of 57.92% and a negative net margin of 2,856.56%. As a group, equities analysts predict that Corbus Pharmaceuticals will post -0.29 EPS for the current year.

A number of large investors have recently made changes to their positions in CRBP. Spire Wealth Management purchased a new position in Corbus Pharmaceuticals during the fourth quarter valued at $28,000. Aries Wealth Management raised its stake in Corbus Pharmaceuticals by 360.7% during the fourth quarter. Aries Wealth Management now owns 107,800 shares of the biopharmaceutical company’s stock valued at $66,000 after buying an additional 84,400 shares during the last quarter. JPMorgan Chase & Co. raised its stake in Corbus Pharmaceuticals by 211.1% during the fourth quarter. JPMorgan Chase & Co. now owns 107,590 shares of the biopharmaceutical company’s stock valued at $66,000 after buying an additional 73,008 shares during the last quarter. Cambridge Investment Research Advisors Inc. raised its stake in Corbus Pharmaceuticals by 27.5% during the fourth quarter. Cambridge Investment Research Advisors Inc. now owns 115,919 shares of the biopharmaceutical company’s stock valued at $71,000 after buying an additional 25,000 shares during the last quarter. Finally, Two Sigma Investments LP purchased a new position in shares of Corbus Pharmaceuticals in the third quarter worth $107,000. Institutional investors and hedge funds own 35.39% of the company’s stock.

Corbus Pharmaceuticals Company Profile (Get Rating)

Corbus Pharmaceuticals Holdings, Inc, a biopharmaceutical company, focuses on the development of immune modulators for immuno-oncology and fibrosis diseases. It develops lenabasum, an oral molecule that selectively activates cannabinoid receptor type 2 (CB2), which is in Phase II clinical trial to treat systemic lupus erythematosus; CRB-601, an anti-integrin monoclonal antibody (mAb) for the treatment of cancer and fibrosis that inhibits the activation of transforming growth factor ß (TGFß); and CRB-602, an anti-avß6/avß8 mAb that blocks the activation of TGFß for the treatment of fibrotic diseases.

Featured Stories

Receive News & Ratings for Corbus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Corbus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.